# Vascepa to Accelerate Lipoprotein Uptake and Elimination

> **NCT03885661** · PHASE1 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 20 (actual)

## Conditions studied

- Lipid Disorder
- Triglycerides High
- Dyslipidemias

## Interventions

- **DRUG:** Icosapent Ethyl 1000 MG [Vascepa]

## Key facts

- **NCT ID:** NCT03885661
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-11
- **Primary completion:** 2018-08
- **Final completion:** 2021-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-11-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03885661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03885661, "Vascepa to Accelerate Lipoprotein Uptake and Elimination". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03885661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*